📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
Latest filing: 2026-08-27 17:39
161 analysed today
FollowTelegram
161
Today
149,562
All-time analysed
42,894
Positive
6,654
Negative
91,341
Neutral
8,605
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
17 announcements match the current filters (relevance ≥ 5).
FDC Secures Delhi High Court Interim Stay on FSSAI Notice; Gets 8 Months to Exhaust Stock
FDC Limited has obtained an interim stay from the High Court of Delhi against an impugned notice issued by FSSAI concerning product mislabeling ('electrolyte'/'electrolyte drink'). The court order, received on August 26, 2026, allows FDC an 8-month window to exhaust its existing inventory and update product labels accordingly. This follows a previous stock seizure intimation dated June 4, 2026 by FSSAI Maharashtra. Management confirmed there is no material adverse financial or operational impact from this order.
Confidence: HIGH
What changedThe High Court granted an interim stay against FSSAI's regulatory notice, providing an 8-month transition window to clear existing stock and update packaging.
Why it mattersAverts immediate product write-offs or sales disruption for energy/electrolyte formulations, ensuring smooth operational continuity for domestic sales.
Transition period granted: 8 monthsOrder receipt date: 26th August, 2026TTM Revenue context: Rs 2191 Cr
📅 Short termRemoves immediate regulatory overhang and prevents disruption in the distribution of affected SKUs.
📈 Long termLimited long-term financial impact as relabeling within 8 months should normalize regulatory compliance without recurring costs.
⚠ Risk flags
- Pending final outcome of the Writ Petition before the Delhi High Court
- Execution risk in updating packaging across distribution channels within 8 months
Key Highlights
High Court of Delhi granted an interim stay on FSSAI notice regarding product mislabeling
FDC allowed 8 months' time to exhaust existing stock bearing 'electrolyte'/'electrolyte drink' descriptors
Order received on August 26, 2026, following prior FSSAI Maharashtra seizure notice dated June 4, 2026
Management states zero material adverse financial or operational impact on the company
👀 What to Watch
Track the execution of product label transitions over the next 8 months and any final rulings from the Delhi High Court regarding FSSAI compliance.
FDC Subsidiary Receives UK MHRA Approval for Atropine 1.0% Eye Drops
FDC Limited's subsidiary, FDC International Ltd, has received Marketing Authorisation from the UK MHRA for Atropine 1.0% w/v Eye Drops. This approval aligns with the company's stated strategy to aggressively target non-US markets like Europe to increase its export revenue, which currently stands at approximately 13% of formulations. Given FDC's TTM revenue of ‹2,171 Cr, this specific product approval strengthens its core ophthalmic portfolio in a regulated market. This comes at a time when the company is looking to offset a 31.2% decline in US revenue observed in H1 FY26.
Confidence: HIGH
What changedFDC has obtained regulatory clearance to market its Atropine 1.0% Eye Drops in the United Kingdom, expanding its international product footprint.
Why it mattersThis approval supports FDC's strategy to diversify its geographic risk, especially after recent revenue headwinds in the US market, and leverages its established expertise in ophthalmic formulations.
TTM Revenue: ‹2,171 CrExport Share (Formulations): 13%Product Concentration: Atropine 1.0% w/vMarket Cap: ‹5,736 Cr
📅 Short termThe news is sentimentally positive for the stock as it validates the company's R&D and regulatory capabilities in a stringent market like the UK.
📈 Long termStructurally, this adds to FDC's portfolio in the high-margin ophthalmic segment and contributes to the long-term goal of outperforming the Indian Pharmaceutical Market growth rate through international expansion.
⚠ Risk flags
- Market competition in the UK for Atropine drops
- Pricing pressure in regulated markets
- Execution risk in international distribution
Key Highlights
Marketing Authorisation received from the Medicines and Healthcare products Regulatory Agency (MHRA), UK.
Approval granted for Atropine 1.0% w/v Eye Drops, Solution.
The approval was secured by the company's subsidiary, FDC International Limited.
FDC is targeting non-US markets to grow its 13% formulation export share.
Company maintains a healthy TTM revenue of ‹2,171 Cr with a low Debt/Equity of 0.01.
👀 What to Watch
Investors should monitor the commercial launch timeline in the UK and track the growth in 'Export Formulations' in upcoming quarterly results to gauge the product's contribution.
9.2% PAT Growth in Q1 FY27; US Business Surges 118% Amid Muted Domestic Sales
FDC reported a modest 3% YoY revenue growth to 668 crore for Q1 FY27, primarily driven by a sharp recovery in international markets. While the core Domestic Formulations segment (85% of sales) saw a 1.9% decline due to subdued performance in key brands like Zifi and Enerzal, the US business grew 118.4% to 34 crore. Profit After Tax (PAT) rose 9.2% to 132 crore, maintaining a healthy margin profile. The company also secured a key US FDA approval for Cefixime Oral Suspension during the quarter.
Confidence: HIGH
What changedFDC's growth engine shifted from domestic to international markets this quarter, with the US and Non-US exports offsetting a rare decline in the domestic formulations business.
Why it mattersDomestic formulations are FDC's primary value driver (85% of revenue); while international growth is positive, the company needs domestic stability to maintain its historical outperformance of the Indian Pharmaceutical Market.
Q1 Revenue: 668 crQ1 PAT: 132 crUS Business Growth: 118.4%Domestic Sales Contribution: 85%Q1 Revenue vs TTM Revenue: 30.8%
📅 Short termThe stock may see neutral to slightly cautious sentiment as the market digests the decline in the core domestic segment despite the bottom-line growth.
📈 Long termFDC's strategy to expand its field force and target non-US markets remains structural; long-term value depends on returning the domestic business to its 14.5% historical growth trajectory.
⚠ Risk flags
- Decline in core domestic formulations revenue
- Subdued performance of high-margin flagship brands
- High concentration in domestic market (85%)
Key Highlights
Consolidated Revenue increased 3.0% YoY to 668 crore.
US Formulation sales surged 118.4% YoY to 34 crore following previous period's volatility.
Domestic Formulations revenue declined 1.9% YoY to 569 crore, impacted by flagship brand performance.
EBITDA margins remained stable at 21.4% compared to 21.6% in the previous year.
Non-US Export Formulations grew 47.7% YoY to 39 crore.
👀 What to Watch
Monitor the recovery of domestic flagship brands (Zifi, Enerzal) in upcoming quarters and the sustainability of the US business growth following the new Cefixime approval.
₹132 Cr Q1 Profit: FDC Reports 9% YoY Growth and Green Energy Investment
FDC Limited reported a steady Q1 FY27 with consolidated revenue growing 4.6% YoY to ₹715.35 cr. Net profit increased by 9.1% to ₹132.39 cr, resulting in an EPS of ₹8.14 compared to ₹7.45 in the previous year's corresponding quarter. Additionally, the board approved a ₹45 lakh investment for a 26% stake in Netra Green Energy to procure solar power for its Roha API plant. This investment is negligible at approximately 0.02% of the company's ₹2,492 cr net worth but aligns with long-term cost-optimization strategies.
Confidence: HIGH
What changedFDC delivered a growth-oriented Q1 and initiated a strategic move toward captive green energy for its API manufacturing facility.
Why it mattersQ1 is typically a high-margin period for FDC; maintaining growth here supports the company's target of outperforming the Indian Pharmaceutical Market growth rate while addressing operational costs.
Revenue (Q1 FY27): ₹715.35 crNet Profit (Q1 FY27): ₹132.39 crYoY Profit Growth: 9.1%Solar Investment: ₹45 lakhsInvestment vs Net Worth: 0.02%
📅 Short termThe stock may see positive sentiment following the profit growth and EPS improvement, reflecting steady domestic performance.
📈 Long termFDC remains a stable domestic-focused player with minimal debt; the green energy shift is a minor but positive step toward manufacturing efficiency.
⚠ Risk flags
- US market product recalls (historical context)
- High R&D spending impact on EBITDA
Key Highlights
Consolidated Revenue from operations grew to ₹715.35 cr in Q1 FY27 from ₹683.91 cr in Q1 FY26.
Net Profit for the quarter increased to ₹132.39 cr, up 9.1% from ₹121.35 cr in the same period last year.
Earnings Per Share (EPS) rose to ₹8.14 from ₹7.45 YoY.
Board approved an investment of up to ₹45 lakhs for a minimum 26% stake in a captive solar power project for the Roha API plant.
Total expenses for the quarter stood at ₹540.65 cr, compared to ₹524.13 cr in Q1 FY26.
👀 What to Watch
Monitor the impact of the new therapeutic divisions (Nutrica) on overall margins and the progress of the Roha API plant's energy cost optimization through the new solar project.
FDC Limited: Maharashtra FDA Seizes 'Enerzal' Stock Over Misbranding Allegations
The Maharashtra Food & Drug Administration (FDA) conducted inspections at FDC's depots in Chhatrapati Sambhaji Nagar and Nagpur on June 3, 2026. During these visits, authorities seized stock of the company's popular brand 'Enerzal' and collected samples for examination regarding alleged misbranding. FDC has clarified that there is no material financial impact on operations as of now and business continues as usual. The company is awaiting the final examination order and intends to pursue legal recourse to resolve the matter.
Key Highlights
FDA Maharashtra seized 'Enerzal' stock at Chhatrapati Sambhaji Nagar and Nagpur depots on June 3, 2026.
The regulatory action is based on alleged misbranding of the product under food safety regulations.
FDC reports no immediate material financial impact on the company's overall operations.
Final examination orders from the Authority are currently pending.
The company plans to take appropriate legal recourse once the final report is received.
👀 What to Watch
Investors should monitor the final FDA report as 'Enerzal' is a significant brand for FDC; any prolonged regulatory hurdle could impact brand equity. No immediate action is required as the company claims no material financial impact currently.
FDC Q4 FY26 PAT Surges 167% YoY to ₹103 Cr; EBITDA Margins Expand to 18.2%
FDC Limited reported a robust Q4 FY26 with revenue growing 18.9% YoY to ₹585 crores, driven by a sharp recovery in export markets and steady domestic growth. Net profit for the quarter skyrocketed by 167.4% to ₹103 crores, supported by a significant EBITDA margin expansion from 11.0% to 18.2%. While the full-year FY26 revenue growth was modest at 3%, the Q4 performance highlights a strong turnaround in the US business, which grew 283% YoY. The company also received US FDA approval for Fluconazole Tablets, strengthening its export pipeline.
Key Highlights
Q4 PAT grew 167.4% YoY to ₹103 crores; EPS increased to ₹6.35 from ₹2.38
EBITDA margins expanded by 720 bps YoY to 18.2% in Q4 FY26 due to operational efficiencies
Export Formulations (US) revenue surged 283.1% YoY in Q4 to ₹39 crores
Domestic Formulations business (78% of Q4 sales) grew 8.5% YoY to ₹452 crores
Full year FY26 revenue reached ₹2,171 crores with a consolidated PAT of ₹281 crores
👀 What to Watch
Investors should view the sharp margin expansion and US business recovery as strong positives; the focus should remain on whether the domestic segment can maintain its Q4 growth momentum.
FDC Q4 FY26 PAT Surges 167% to ₹103 Cr; EBITDA Margins Expand to 18.2%
FDC Limited reported a strong Q4 FY26 performance with revenue growing 18.9% YoY to ₹585 crores, driven by a massive 99.3% jump in export formulations. Profitability saw a significant boost as PAT surged 167.4% YoY to ₹103 crores, supported by EBITDA margins expanding from 11.0% to 18.2%. While the domestic formulations business showed recovery with 8.5% growth in Q4, the full-year domestic growth remained muted at 0.1% due to weakness in core brands like Zifi and Electral. The US business showed strong momentum with 283% growth in the quarter, signaling a turnaround in international markets.
Key Highlights
Q4 FY26 Revenue grew 18.9% YoY to ₹585 Cr, while full-year FY26 Revenue reached ₹2,171 Cr (+3.0%).
Q4 PAT skyrocketed 167.4% YoY to ₹103 Cr, with EPS rising to ₹6.35 from ₹2.38.
EBITDA margins improved significantly to 18.2% in Q4 from 11.0% in the previous year's quarter.
US Export Formulations revenue grew by 283.1% in Q4, driven by improved execution and demand.
Domestic Formulations (78% of Q4 sales) grew 8.5% in Q4, recovering from a flat performance earlier in the year.
👀 What to Watch
Investors should monitor if the Q4 recovery in domestic brands and the strong US export momentum are sustainable. The significant margin expansion is a positive sign of operational efficiency and warrants a closer look at the company's cost-management strategies.
FDC Q4 Net Profit Surges 122% YoY to ₹107 Crore; Revenue Up 17%
FDC Limited reported a robust performance for Q4 FY26, with standalone revenue growing 17.1% YoY to ₹564.36 crore. Net profit for the quarter saw a significant jump of 122% YoY, reaching ₹107.07 crore, driven by strong operational performance and higher other income. For the full year FY26, the company recorded a net profit of ₹285.92 crore, up from ₹273.63 crore in FY25, despite a one-time exceptional charge of ₹20.79 crore related to new labor code provisions. The company maintains a strong balance sheet with total equity of ₹2,492.64 crore.
Key Highlights
Q4 FY26 Revenue from operations rose 17.1% YoY to ₹564.36 crore from ₹482.00 crore.
Q4 FY26 Net Profit spiked 122% YoY to ₹107.07 crore compared to ₹48.22 crore in the previous year.
Full-year FY26 EPS increased to ₹17.56 from ₹16.81 in the prior fiscal year.
Recognized a one-time exceptional expense of ₹2,078.91 lakhs for estimated obligations under New Labour Codes.
Other income for the quarter significantly increased to ₹47.16 crore from ₹31.43 crore YoY.
👀 What to Watch
Investors should take note of the strong Q4 recovery and margin expansion, which suggests improved operational efficiency. The company remains a stable pharmaceutical play with consistent dividend payouts and a debt-free balance sheet.
FDC Q4 FY26 Net Profit Jumps 122% YoY to Rs 107 Cr; Revenue Up 17%
FDC Limited reported a robust Q4 FY26 with standalone revenue rising 17% YoY to Rs 564.36 crore. Net profit for the quarter more than doubled, reaching Rs 107.07 crore compared to Rs 48.22 crore in the same period last year, driven by higher operational income and controlled expenses. For the full year FY26, the company achieved a net profit of Rs 285.92 crore, even after accounting for a Rs 20.79 crore exceptional item related to new labor regulations. The company's balance sheet remains healthy with total equity growing to Rs 2,492.64 crore.
Key Highlights
Q4 FY26 Revenue from operations grew 17.1% YoY to Rs 56,436 lakhs.
Quarterly Net Profit surged 122% YoY to Rs 10,707 lakhs from Rs 4,822 lakhs.
Full-year FY26 Net Profit stood at Rs 28,592 lakhs, up from Rs 27,363 lakhs in FY25.
Recognized a one-time exceptional expense of Rs 2,079 lakhs due to New Labour Code obligations.
Annual Earnings Per Share (EPS) increased to Rs 17.56 from Rs 16.81 in the previous fiscal year.
👀 What to Watch
The sharp jump in quarterly profitability suggests strong operational leverage and improved product mix towards the end of the fiscal year. Investors should monitor the impact of the new labor codes on future employee costs, but the overall growth trajectory remains positive.
FDC Receives USFDA Approval for Cefixime Oral Suspension (100mg/5mL and 200mg/5mL)
FDC Limited has received Abbreviated New Drug Application (ANDA) approval from the United States Food and Drug Administration (USFDA) for Cefixime for Oral Suspension USP. The approval covers two dosage strengths: 100 mg/5 mL and 200 mg/5 mL. This regulatory milestone allows the company to market this antibiotic in the United States, expanding its international product portfolio. This development is expected to contribute to the company's export revenue growth in the highly regulated US market.
Key Highlights
Granted ANDA approval by the USFDA for Cefixime for Oral Suspension USP.
Approval includes two specific strengths: 100 mg/5 mL and 200 mg/5 mL.
The product is a cephalosporin antibiotic used to treat various bacterial infections.
Strengthens FDC's presence and product offerings in the US pharmaceutical market.
👀 What to Watch
Investors should monitor the company's commercialization strategy and launch timeline for this product in the US market. This approval is a positive indicator of FDC's regulatory compliance and potential for international revenue growth.
FDC Limited Faces GST Inspection at Mumbai Corporate Office
The Goods & Service Tax (GST) Department of Maharashtra initiated an inspection and search at FDC Limited's corporate office in Mumbai on February 10, 2026. The proceedings, which commenced at 16:15 hours, are focused on tax payments, input tax credit (ITC) claims, and refunds under the MGST Act, 2017. The company has stated that business operations continue as usual and there is no immediate financial impact from the initiation of this search. FDC is currently cooperating with the authorities and will disclose any material developments upon the conclusion of the inspection.
Key Highlights
GST Department initiated search proceedings at FDC's Mumbai corporate office on February 10, 2026
Inspection relates to tax payments, input tax credit claims, and refund processes under Section 67 of MGST Act
Company reports zero immediate financial impact and no disruption to ongoing business operations
FDC is extending full cooperation to the Deputy Commissioner of State Tax, Maharashtra
👀 What to Watch
Investors should monitor for any follow-up disclosures regarding tax demands or penalties resulting from this search. While operations are unaffected, regulatory scrutiny can lead to short-term sentiment-driven volatility.
FDC Q3 FY26 Results: Revenue Flat at ₹465 Cr, PAT Declines 23.6% YoY to ₹28 Cr
FDC Limited reported a stagnant Q3 FY26 with revenue from operations at ₹465 crore, a marginal 0.1% YoY growth. Profit After Tax (PAT) saw a sharp decline of 23.6% YoY to ₹28 crore, primarily due to exceptional items and a 5.2% contraction in the core Domestic Formulations business. While the domestic segment struggled with lower sales of top brands like Zifi and Electral, the Export Formulations segment provided a silver lining with 55% YoY growth. EBITDA margins showed slight improvement, rising to 11.2% from 10.1% in the previous year.
Key Highlights
Revenue from operations remained flat at ₹465 crore (+0.1% YoY), while 9M FY26 revenue fell 1.9%.
PAT dropped 23.6% YoY to ₹28 crore, with EPS declining from ₹2.28 to ₹1.74.
Domestic Formulations, contributing 80% of revenue, declined 5.2% YoY to ₹369 crore.
Export Formulations grew 55% YoY to ₹71 crore, driven by a 199% surge in US sales to ₹25 crore.
EBITDA increased 12.1% YoY to ₹52 crore, with margins expanding 110 bps to 11.2%.
👀 What to Watch
Investors should remain cautious as the company's primary domestic engine is showing signs of weakness in its flagship brands. While the US FDA approvals and export growth are positive, the significant drop in bottom-line profit warrants a wait-and-watch approach for signs of domestic recovery.
FDC Limited Sets Feb 11, 2026, as Record Date for First Interim Dividend of FY 2025-26
FDC Limited has officially designated February 11, 2026, as the record date for its first interim dividend for the financial year 2025-26. This date is used to identify the shareholders eligible to receive the dividend payment. The announcement follows the company's regulatory compliance under SEBI (LODR) Regulations, 2015. While the specific dividend amount per share was not detailed in this specific record date filing, it confirms the upcoming cash distribution to eligible investors.
Key Highlights
The record date for the first interim dividend of FY 2025-26 is fixed as Wednesday, February 11, 2026.
The notification is issued pursuant to Regulation 42 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
Only shareholders whose names appear in the company's register as of the record date will be eligible for the payout.
👀 What to Watch
Investors looking to qualify for the dividend should ensure they hold the shares in their demat account before the ex-dividend date. Current shareholders should monitor for the specific dividend amount to assess the yield on their investment.
FDC Declares ₹5 Interim Dividend; Q3 Consolidated Net Profit Declines to ₹28.30 Crore
FDC Limited has declared a first interim dividend of ₹5 per equity share for FY 2025-26, with the record date set for February 11, 2026. The company's consolidated revenue for Q3 FY26 remained flat at ₹464.71 crore compared to ₹464.11 crore in the same quarter last year. Consolidated net profit for the quarter fell by 23.6% to ₹28.30 crore, down from ₹37.04 crore YoY. This decline was significantly impacted by a one-time exceptional expense of ₹20.79 crore related to the implementation of New Labour Codes.
Key Highlights
Declared an interim dividend of ₹5 per share on a face value of ₹1 (500% payout).
Consolidated Q3 revenue stood at ₹464.71 crore, showing negligible growth from ₹464.11 crore YoY.
Net profit (consolidated) decreased to ₹28.30 crore from ₹37.04 crore in the previous year's quarter.
Recognized a one-time exceptional cost of ₹20.79 crore due to regulatory changes in wage definitions under New Labour Codes.
Standalone EPS for the quarter declined to ₹1.67 from ₹2.24 in Q3 FY25.
👀 What to Watch
Investors should focus on the steady dividend yield but remain cautious regarding the stagnant top-line growth. The profit dip is largely due to a non-recurring regulatory expense, so underlying operational efficiency should be monitored in the coming quarters.
FDC Q3 PAT Drops 23.6% to ₹28.3 Cr on Exceptional Item; Declares ₹5 Interim Dividend
FDC Limited reported a flat consolidated revenue of ₹464.71 crore for the quarter ended December 31, 2025. Net profit for the quarter declined by 23.6% YoY to ₹28.30 crore, primarily due to a one-time exceptional charge of ₹20.79 crore related to the implementation of New Labour Codes. Despite the lower net profit, the company maintained its shareholder reward policy by declaring a first interim dividend of ₹5 per share. On a nine-month basis, the company's revenue and PAT have seen a slight contraction compared to the previous fiscal year.
Key Highlights
Consolidated Revenue from operations remained stagnant at ₹464.71 crore vs ₹464.11 crore YoY.
Net Profit after tax fell to ₹28.30 crore from ₹37.04 crore YoY, impacted by a ₹20.79 crore exceptional expense.
Declared a first interim dividend of ₹5 per equity share (500% of face value) with a record date of Feb 11, 2026.
Profit before tax and exceptional items actually grew 11.7% YoY to ₹57.17 crore, indicating stable core operations.
Nine-month consolidated PAT stands at ₹178.02 crore, down 22% from ₹228.12 crore in the previous year.
👀 What to Watch
Investors should look past the headline profit decline as it was caused by a non-recurring regulatory expense; however, the lack of revenue growth warrants a cautious outlook. The healthy dividend payout provides a decent yield for long-term holders.
FDC Receives USFDA Approval for Fluconazole Tablets in Multiple Strengths (50mg to 200mg)
FDC Limited has received Abbreviated New Drug Application (ANDA) approval from the USFDA for Fluconazole Tablets USP. The approval covers four specific dosage strengths: 50 mg, 100 mg, 150 mg, and 200 mg. This regulatory milestone allows the company to market and sell this antifungal medication in the United States. This development is expected to strengthen FDC's international product portfolio and contribute to its export revenue growth in the highly regulated US market.
Key Highlights
Received USFDA approval for Fluconazole Tablets USP on January 9, 2026.
Approval encompasses four dosage strengths: 50 mg, 100 mg, 150 mg, and 200 mg.
Expands the company's footprint in the US pharmaceutical market.
Fluconazole is a widely used antifungal medication, indicating a significant market opportunity.
👀 What to Watch
Investors should view this as a positive development for FDC's export business. Monitor the company's upcoming quarterly results for commentary on the commercial launch and market share expectations in the US.
FDC Limited Receives GST Demand Notice of ₹15.61 Crore for FY 2021-22
FDC Limited has received a demand notice from the GST Department, Maharashtra, totaling ₹15.61 crore for the financial year 2021-22. The demand includes a differential tax of ₹8.42 crore, interest of ₹6.35 crore, and a penalty of ₹0.84 crore due to alleged misclassification of tax rates. The authority claims the company charged 18% GST instead of the applicable 28% plus compensation cess. FDC intends to contest the order through legal remedies and believes there will be no material financial impact on its operations.
Key Highlights
Total demand of ₹15.61 crore received from Deputy Commissioner of State Tax, Mumbai.
Demand consists of ₹8.42 crore tax, ₹6.35 crore interest, and ₹84.22 lakh penalty for FY 2021-22.
Allegation involves misclassification of GST rates, charging 18% instead of the required 28% plus cess.
Company plans to seek legal remedy and contest the order in its entirety.
Management does not foresee any material financial impact on account of this order.
👀 What to Watch
Investors should monitor the progress of the legal appeal as a final unfavorable ruling would result in a cash outflow of ₹15.61 crore. No immediate panic is necessary as the company is actively contesting the demand.
